An international group of clinicians has proposed time to next treatment (TTNT) as a clinically meaningful endpoint to be applied in future studies of primary cutaneous T-cell lymphoma (CTCL). Writing in the Open Access journal Cancers, the UK, US and Australian authors said TTNT was a useful surrogate for the duration of clinical benefit. It ...
Time to next treatment endpoint suits complexity of CTCL
By Mardi Chapman
10 Sep 2020